Member Profile

Founded in 2005, Eusol Biotech Co., Ltd. is committed to developing innovative treatments to meet the unmet medical needs of neurological diseases and injuries that are difficult to treat. It’s aimed primarily on the research and development of ES135 (rhFGF1) as a new drug for the treatment of spinal cord and peripheral nerve injuries, which can help patients with nerve injuries to restore their functions and improve the patients’ quality of daily life. Additional research on other potential indications of ES135 have also been conducted. ES135 (rhFGF1), the investigational new drug has been patented in Taiwan, the European Union, the United States, China, and other countries as a curative molecule with medicinal applications. It is a genetically recombinant human acid fibroblast growth factor with medical utility. In long-term cooperation with the medical team of Taipei Veterans Hospital (TVGH) Neuroregenerative Medicine Center, the pivotal phase 3 clinical trial is currently undergoing. In addition to ES135, Eusol has also developed a three-in-one new dosage form of combination sleep aid (SM-1) as a sleep aid. SM-1 is designed to be a new formulation in combination of sequential release of 3 drugs to improve sleeping quality for people with insomnia. One phase 1, two phase 2 and a phase 3 clinical trials have been completed in Europe and the United States, respectively. In addition to focusing on new drug development, Eusol is currently vigorously transforming into a biotech company with diversified product development.